"GlycoVision results featured at ESMO 2024: read the interview here to learn how InterVenn is powering new prognostic and predictive biomarkers!
Products and Services
Products
Services
Science and Technology
Enabling Technologies
Glycoproteomics
Publications
For Investors
For Investors
News and Events
Company
About Us
Leadership Team
Careers
Contact
30 Blood-based glycoprotein signatures in advanced non-small-cell lung carcinoma (NSCLC) receiving first-line immune checkpoint blockade
By continuing to browse this site, you agree to our
privacy policy
and use of cookies.
I Agree
Get in touch
